Objective. Several studies have demonstrated that the secreted glycoprotein and integrin ligand milk fat globuleassociated protein with epidermal growth factor-and factor VIII-like domains (MFG-E8) negatively regulates fibrosis in the liver, lungs, and respiratory tract. However, the mechanisms and roles of MFG-E8 in skin fibrosis in systemic sclerosis (SSc) have not been characterized. We undertook this study to elucidate the role of MFG-E8 in skin fibrosis in SSc.
INTRODUCTION
Systemic sclerosis (SSc) is a connective tissue disorder characterized by the development of fibrosis in the skin and internal organs, vascular disorders, and autoimmunity (1, 2) . SSc patients develop various vasculopathy-induced vascular disorders, such as Raynaud's phenomenon, abnormal nailfold capillaries, and digital ulcers (1, 3, 4) . Vascular disorders precede the onset of fibrosis, and vasculopathy is thought to be a primary event in the pathogenesis of SSc (1, 2) . It is believed that vasculopathy induces dysfunction of endothelial cells (ECs) and pericytes, hypoxia, and overproduction of endothelin 1, resulting in the activation of fibroblasts around damaged vessels and the induction of fibrosis (2, 5) . However, the underlying mechanism of fibrosis induction by vasculopathy remains unknown.
Milk fat globule-associated protein with epidermal growth factor (EGF)-and factor VIII-like domains (MFG-E8) is a secreted glycoprotein composed of 2 N-terminal EGF-like domains and 2 C-terminal discoidin-like domains that are homologous to blood coagulation factors 5 and 8 (6, 7) . One EGF-like domain contains the RGD domain that binds to αvβ3/β5 integrin, and the C-domains bind to phosphatidylserine and type I collagen (8, 9) . MFG-E8 accelerates phagocytosis of apoptotic cells by bridging phosphatidylserine in apoptotic cells and αvβ3/β5 integrin in phagocytes, resulting in the suppression of inflammatory responses (10) (11) (12) . We previously found that pericytes and mesenchymal stem cells (MSCs) secrete large amounts of MFG-E8 and that pericyte-and MSC-derived MFG-E8 promotes angiogenesis in intractable diabetic wounds, cutaneous ischemiareperfusion injury, and melanoma tumors (13) (14) (15) (16) (17) (18) .
Regarding the regulation of fibrosis by MFG-E8, it has been reported that the expression of MFG-E8 was decreased in cirrhotic liver tissue; recombinant MFG-E8 (rMFG-E8) inhibited the expression of transforming growth factor β receptor type I (TGFβRI) by binding to αvβ3 integrin on human hepatic stellate cells, resulting in the inhibition of TGFβ signaling in vitro; and injection of rMFG-E8 into mice had an antifibrotic effect on thioacetamide-induced liver fibrosis in vivo (19) . However, it remains unknown how MFG-E8 regulates skin fibrosis in SSc.
It has been reported that MFG-E8 is implicated in the pathogenesis of autoimmune disorders, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The serum MFG-E8 level in SLE patients was higher than that in healthy individuals (20) , and aged MFG-E8-knockout (KO) mice developed glomerulonephritis and showed antinuclear antibody (ANA) production (21) . Serum MFG-E8 levels in RA patients and arthritic mice were significantly lower than those in healthy controls, and MFG-E8-KO mice exhibited exacerbated arthritis (22) .
TGFβ, a pivotal cytokine in fibrosis, is secreted from cells as a large latent complex composed of bioactive peptide of TGFβ and latency-associated protein, which in turn binds to latent TGFβ binding protein. Secreted latent TGFβ is stored in the extracellular matrix (ECM), and activated TGFβ is released by the binding of the RGD sequence in the latent TGFβ complex to αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8 integrins (23, 24) . In SSc fibroblasts, overexpression of αvβ5 integrin leads to the activation of TGFβ1 and skin fibrosis (25) . Furthermore, SSc-like skin fibrosis, ANA production, and TGFβ signaling activation were demonstrated in fibrillin 1 mutant mice in which the RGD domain of fibrillin 1 was changed to an RGE domain, resulting in inhibition of the binding of fibrillin to αv integrin (26) . These findings strongly suggest that the binding between αv integrin on fibroblasts and latent TGFβ complex might be implicated in the pathogenesis of skin fibrosis in SSc.
MFG-E8 binds to αvβ3/β5 integrin via the RGD domain, which suggests that MFG-E8 might be associated with the pathogenesis of skin fibrosis in SSc through modulation of the interaction between αv integrin and latent TGFβ. However, the roles of MFG-E8 in the pathogenesis of skin fibrosis in SSc have not been investigated. In this study, we examined the expression of MFG-E8 in fibrotic lesions and the serum MFG-E8 level in SSc patients, and we analyzed the effects of the addition of MFG-E8 on latent TGFβ-induced fibrosis in fibroblasts in vitro. Furthermore, we assessed the effect of MFG-E8 depletion or injection on skin fibrosis in a mouse model of bleomycin-induced fibrosis and in a TSK mouse model, which are experimental models of SSc.
MATERIALS AND METHODS
Patients. All of the SSc patients fulfilled the American College of Rheumatology/European League Against Rheumatism 2013 classification criteria (27) . The serum samples were obtained from 44 Japanese patients with SSc (35 women and 9 men, mean ± SD age 60.0 ± 2.1 years) and 28 age-, race-, and sexmatched healthy volunteers. Twenty-eight patients were classified as having limited cutaneous SSc and 16 were classified as having diffuse cutaneous SSc (dcSSc) according to LeRoy et al (28) . Skin sclerosis was assessed using the modified Rodnan skin thickness score (29) . We obtained human dermal fibroblasts by performing skin biopsies on affected dorsal forearm areas of dcSSc patients and age-, race-, and sex-matched healthy volunteers. For immunohistochemical staining of MFG-E8, we obtained human skin tissues in the same way from 7 dcSSc patients and 6 age-, race-, and sex-matched healthy volunteers. The study was approved by the Institutional Review Board and the local research ethics committee of Gunma University and was conducted according to the principles of the Declaration of Helsinki.
Immunohistochemistry and immunofluorescence staining. Frozen sections (4 μm thick) of human skin were fixed in 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS) at room temperature for 1 hour. Dermal fibroblasts from SSc patients were seeded in 8-well culture slides (BD Biosciences), and cells were either left untreated or treated with latent TGFβ1 (2 ng/ml; R&D Systems) with or without rMFG-E8 (100 ng/ml; R&D Systems) for 24 hours and fixed in 4% PFA at room temperature for 1 hour. After being blocked with 3% skim milk-PBS supplemented with 5% normal goat serum for 30 minutes at room temperature, skin tissues or cells were stained with mouse anti-human MFG-E8 polyclonal antibody (R&D Systems), rabbit anti-CD31 antibody (Abcam), and anti-α-smooth muscle actin (anti-α-SMA) antibody (Sigma) followed by staining with Alexa Fluor 488-or Alexa Fluor 568-conjugated secondary antibodies (Invitrogen). Tissues or cells were mounted in ProLong Gold antifade reagent (Invitrogen). Immunofluorescence images were collected and visualized with an FV10i-DOC confocal laser scanning microscope (Olympus).
Sections (4 μm thick) of mouse skin or lung embedded in paraffin were stained with hematoxylin and eosin (H&E) or Masson's trichrome. Skin fibrosis was quantified by measuring the thickness of the dermis, which was defined as the distance from the epidermal-dermal junction to the dermal-subcutaneous junction, at 6 randomly selected microscopic fields. Lung fibrosis was quantified by lung fibrosing score as described previously (30) . Lung fibrosis was graded on a scale of 0 to 8 by examining 10 randomly selected fields. The cri teria for grading lung fibrosis were as follows: grade 0 = normal lung; grade 1 = minimal fibrous thickening of alveolar or bronchiolar walls; grade 3 = moderate thickening of walls without obvious damage to lung architecture; grade 5 = increased fibrosis with definite damage to lung structure and formation of fibrous bands or small fibrous masses; grade 7 = severe distortion of structure and large fibrous area; grade 8 = total fibrous obliteration of the field. Grades 2, 4, and 6 were used as intermediate pictures between the aforementioned criteria.
For immunohistochemical staining, tissue sections of human or mouse skin were treated for antigen retrieval with a pressure cooker for 10 minutes at 121°C. After blocking using Peroxidase Blocking (Dako) for 5 minutes and Protein Block (Dako) for 10 minutes, the sections were incubated with mouse anti-human MFG-E8 polyclonal antibody, anti-α-SMA antibody, anti-CD3 antibody (Abcam), anti-CD68 antibody (Bio-Rad), anti-CD31 antibody (BD Biosciences), and anti-NG2 poly clonal antibody (Millipore). After washing, the sections were incubated with a horseradish peroxidaselabeled polymer-conjugated secondary antibody (EnVision+; Dako). Finally, color was developed with 3,3′-diaminobenzidine tetrahydrochloride. Numbers of α-SMA+, CD3+, CD68+, CD31+, and NG2+ cells in the dermis were determined by counting in 6 random microscopic fields in 3 mice per group.
Reverse transcriptase-polymerase chain reaction analysis. To examine the effect of rMFG-E8 on TGFβ-or latent TGFβ-induced fibrosis in SSc fibroblasts, the cells were pretreated with rMFG-E8 (100 ng/ml) for 1 hour and then stimulated with TGFβ1 (2 ng/ml; R&D Systems) or latent TGFβ (2 ng/ ml) for 24 hours. To examine the effect of RGD-MFG-E8-Ig or RGE-MFG-E8-Ig on latent TGFβ-induced fibrosis-related gene expression, NIH3T3 fibroblasts were pretreated with RGD-MFG-E8-Ig or RGE-MFG-E8-Ig (100 ng/ml) for 1 hour and then stimulated with latent TGFβ (2 ng/ml) for 12 hours. RGD-MFG-E8-Ig and RGE-MFG-E8-Ig were generated and used as previously described (31) . RGD-MFG-E8-Ig is a fusion protein that consists of the N-terminal EGF-like domains (E1 and E2) and the linker region fused with the hinge-containing Fc region of human IgG1 (31) . RGE-MFG-E8-Ig is the corresponding point mutant of MFG-E8-Ig in which aspartic acid (D) in the RGD motif is replaced by glutamic acid (E) (for further details, see Supplementary Materials and Methods, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40701/abstract).
Western blot assay.
Western blot analyses were performed according to previously described protocols (31, 32) . To examine the effect of rMFG-E8 on TGFβ-or latent TGFβ-induced fibrosis-related protein expression in SSc fibroblasts, the cells were pretreated with rMFG-E8 (100 ng/ml) for 1 hour and then stimulated with TGFβ1 (2 ng/ml) or latent TGFβ (2 ng/ml) for 48 hours. To examine the effect of RGD-MFG-E8-Ig or RGE-MFG-E8-Ig on latent TGFβ-induced fibrosis-related protein expression, NIH3T3 fibroblasts were pretreated with RGD-MFG-E8-Ig or RGE-MFG-E8-Ig (100 ng/ml) for 1 hour and then stimulated with latent TGFβ (2 ng/ml) for 12 hours (for further details, see Supplementary Materials and Methods, http://onlinelibrary.wiley. com/doi/10.1002/art.40701/abstract).
Mouse model of bleomycin-induced fibrosis and TSK mouse model. Dermal fibrosis was induced in 8-week-old C57BL/6 mice (Japan SLC) with injections of bleomycin. Injections of 300 μl of bleomycin (Nippon Kayaku) at a concentration of 1 mg/ml were given 5 times per week for 2 weeks as previously described (33, 34) . Injections of 300 μl of PBS were used as controls for treatment with bleomycin. To examine the effect of rMFG-E8, mice received subcutaneously 400 ng/day rMFG-E8 dissolved in 50 μl of PBS or PBS alone 5 times per week for 2 weeks. MFG-E8-KO C57BL/6 mice were generated, characterized, and genotyped as previously described (13, 15, 16, 18, 35) . MFG-E8-KO mice were generated by interbreeding homozygous animals carrying the targeted MFG-E8 allele. TSK mice (TSK/+: B6.Cg-Fbn1
Tsk /J), which had genetic mutations in fibrillin 1, were purchased from The Jackson Laboratory. MFG-E8 wild-type TSK (WT TSK/+) mice and MFG-E8-KO TSK (MFG-E8 −/− TSK/+) mouse littermates were generated by crossing MFG-E8 +/− TSK/+ parents. Mice ages 8-12 weeks were used for all experiments. Mice were bred and maintained in the Institute of Experimental Animal Research of Gunma University under specific pathogen-free conditions. All experiments were approved by the Gunma University Animal Care and Experimentation Committee and carried out in accordance with approved guidelines.
Quantitative assessment of collagen content. Total soluble collagen in the skin was quantified using a Sircol collagen assay (Biocolor) according to the manufacturer's protocol and the previously described protocols (36) .
Measurement of serum levels of MFG-E8, ANAs, and anti-topoisomerase I (anti-topo I).
A specific enzymelinked immunosorbent assay (ELISA) kit (R&D Systems) was used to measure serum MFG-E8 levels according to the manufacturer's protocol. ANAs were assessed with an indirect immunofluorescence kit using HEp-2 substrate cells (Medical and Biological Laboratories) as described (37) . To measure anti-topo I, a specific ELISA kit (Medical and Biological Laboratories) was used according to the manufacturer's protocol.
Statistical analysis. P values were calculated by Student's t-test or one-way analysis of variance followed by the Bonferroni post hoc test for multiple comparisons. Data are reported as the mean ± SEM.
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RESULTS
Decreased expression of MFG-E8 in ECs and pericytes/vascular smooth muscle cells (VSMCs) of lesional skin and low serum MFG-E8 levels in SSc patients. We first examined the expression of MFG-E8 in the sclerotic skin lesions of SSc patients and healthy individuals by immunofluorescence staining. In the skin of healthy individuals, MFG-E8 staining was mainly observed in and around CD31+ vascular ECs, especially being colocalized with α-SMA+ pericytes and VSMCs ( Figure 1A ). Dermal fibroblasts in normal skin were slightly positive for MFG-E8 staining. In contrast, MFG-E8 staining around blood vessels in skin lesions of SSc patients was reduced compared with that in normal skin ( Figure 1A) . The extent of MFG-E8 staining in dermal fibroblasts from SSc patients was nearly the same as that in normal skin fibroblasts. Immunohistochemistry indicated that MFG-E8 staining around capillaries and small blood vessels in the dermis was reduced in the skin of SSc patients ( Figure 1B ; also see Supplementary Table 1 and Supplementary Figure 1 , http://online library.wiley.com/doi/10.1002/art.40701/abstract). There was no difference in expression of messenger RNA (mRNA) for MFG-E8 between normal and SSc cultured fibroblasts ( Figure 1C) . In addition, serum MFG-E8 levels in SSc patients were significantly lower than those in healthy individuals ( Figure 1D ). These results suggest that MFG-E8 expression in ECs and pericytes/VSMCs in the skin and serum MFG-E8 levels might be decreased in SSc patients. 
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Recombinant MFG-E8 inhibits latent TGFβ-induced fibrosis-related gene/protein expression but not TGFβ-induced fibrosis-related gene/protein expression in SSc fibroblasts. It is well known that latent TGFβ binds to αv in tegrin, and thereafter active TGFβ is released from the latent complex (23, 24) . Since MFG-E8 binds to αv integrin, we hypothesized that rMFG-E8 might affect TGFβ signaling by interfering with TGFβ activation. Therefore, we next examined the effect of rMFG-E8 addition on latent TGFβ-induced fibrosis-related gene/protein expression in SSc fibroblasts. Type I collagen is the major ECM in the dermis of skin, and it is overexpressed in sclerotic skin lesions in SSc (38) . Myofibroblasts are primarily involved in fibrosis by overproducing the ECM, and they express α-SMA. The number of α-SMA+ myofibroblasts is increased in sclerotic skin lesions in SSc (38) . CCN2 (also known as connective tissue growth factor) is the member of the CCN family of matricellular proteins associated with fibrosis (39) . CCN2 is overexpressed in SSc fibroblasts and plays an important role in the production and maintenance of fibrotic lesions in SSc (40) . In SSc fibroblasts, latent TGFβ enhanced expression of mRNA for type I collagen, α-SMA, and CCN2, and this was significantly inhibited upon addition of rMFG-E8 (Figures 2A-C) . Furthermore, the elevated protein levels of type I collagen, α-SMA, and p-Smad2 induced by latent TGFβ were significantly inhibited by rMFG-E8 treatment ( Figures 2D and E) .
Akt activates various cell functions such as proliferation, migration, and adhesion, leading to the enhancement of fibrosis. In SSc fibroblasts, p-Akt induced by latent TGFβ was also significantly inhibited by rMFG-E8 treatment (see Supplementary Figure  2A , http://onlinelibrary.wiley.com/doi/10.1002/art.40701/abstract). Focal adhesion kinase (FAK) is important for cell adhesion. Phosphorylated FAK induced by latent TGFβ was slightly inhibited by rMFG-E8 treatment, but this difference did not reach statistical significance (see Supplementary Figure 2B ). Immunofluorescence staining indicated that latent TGFβ-induced α-SMA expression in SSc fibroblasts was inhibited by rMFG-E8 ( Figure 2F ). Expression of mRNA for TGFβRI and TGFβRII in SSc fibroblasts treated with latent TGFβ was not inhibited by rMFG-E8 ( Figures 2G and H) .
We next examined whether rMFG-E8 also inhibits TGFβ-induced fibrosis-related gene/protein expression in SSc fibroblasts. The TGFβ-induced increases in expression of mRNA for type I collagen, α-SMA, and CCN2 were not inhibited by the addition of rMFG-E8 (see Supplementary Figures 3A-C , http:// onlinelibrary.wiley.com/doi/10.1002/art.40701/abstract). Furthermore, TGFβ-induced increases in protein levels of type I collagen, α-SMA, and p-Smad2 were not inhibited by rMFG-E8 treatment (see Supplementary Figures 3D and E) , although the expression of type I collagen, α-SMA, and CCN2 tended to be increased by rMFG-E8 treatment. The expression of TGFβRI and TGFβRII in SSc fibroblasts treated with TGFβ was not affected by rMFG-E8 (see Supplementary Figures 3F and G) . These results suggest that rMFG-E8 inhibits latent TGFβ-induced fibrosisrelated gene/protein expression but not TGFβ-induced fibrosisrelated gene/protein expression in SSc fibroblasts.
MFG-E8 inhibits latent TGFβ-induced fibrosis-related gene/protein expression by binding to αv integrin via the RGD domain in fibroblasts.
We next examined the effects of RGD-MFG-E8-Ig and RGE-MFG-E8-Ig on latent TGFβ-induced fibrosis-related gene/protein expression in NIH3T3 fibroblasts. We have previously reported that RGE-MFG-E8-Ig, the corresponding RGE point mutant, cannot bind to αv integrin on cultured cells (31) . In the present study, we found that RGD-MFG-E8-Ig significantly inhibited latent TGFβ-induced expression of mRNA for type I collagen and CCN2, while RGE-MFG-E8-Ig did not ( Figures 3A  and C) . Furthermore, latent TGFβ-induced protein expression of type I collagen was inhibited by RGD-MFG-E8-Ig but not by RGE-MFG-E8-Ig ( Figure 3D ). We did not observe obvious differences in α-SMA expression between RGD-MFG-E8-Ig-and RGE-MFG-E8-Ig-treated fibroblasts ( Figures 3B and D) . These results suggest that the inhibitory action of MFG-E8 on latent TGFβ-induced fibrosis-related gene/protein expression might be competitively mediated by the binding of the RGD domain of MFG-E8 to αv integrin in fibroblasts.
Bleomycin-induced skin and pulmonary fibrosis are exacerbated by deficiency of MFG-E8. To assess the role of MFG-E8 in tissue fibrosis in vivo, we examined bleomycininduced skin and pulmonary fibrosis in MFG-E8 WT and MFG-E8-KO C57BL/6 mice. Bleomycin-induced dermal thickness in MFG-E8-KO mice was significantly increased compared with that in WT mice ( Figures 4A and C) . The amount of bleomycininduced dermal collagen was significantly larger in MFG-E8-KO mice than in WT mice, as indicated by Masson's trichrome staining ( Figure 4B ). In addition, bleomycin-induced pulmonary fibrosis in MFG-E8-KO mice was significantly more intense than that in WT mice (Figures 4D-F) . Expression of mRNA for type I collagen, CCN2, and α-SMA in lesional skin was significantly increased in bleomycin-treated MFG-E8-KO mice compared to bleomycintreated WT mice ( Figure 4G ). Expression of mRNA for TGFβ and interleukin-6 (IL-6) tended to be higher in bleomycin-treated MFG-E8-KO mice, but the differences did not reach statistical significance ( Figure 4G ). The number of α-SMA+ myofibroblasts in the skin of bleomycin-treated MFG-E8-KO mice was increased, while the numbers of CD3+ T cells, CD68+ macrophages, CD31+ ECs, and NG2+ pericytes in the 2 groups were not significantly different ( Figures 4H and I) . These results suggest that MFG-E8 negatively regulates bleomycin-induced skin and pulmonary fibrosis in mice.
Skin and pulmonary fibrosis in TSK/+ mice are exacerbated by deficiency of MFG-E8. We further examined skin and pulmonary fibrosis in MFG-E8 WT TSK/+ mice and MFG-E8 -/-TSK/+ mice to assess the role of MFG-E8 in tissue fibrosis in vivo. TSK mice spontaneously develop skin fibrosis because of a partial in-frame duplication in the fibrillin 1 gene, and they are known as an experimental model of SSc (41) (42) (43) . The hypodermal thickness in MFG-E8 -/-TSK/+ mice was significantly increased compared with that in MFG-E8 WT TSK/+ mice ( Figures 5A-C) . H&E and Masson's trichrome staining of the lungs indicated that infiltration of inflammatory cells and lung fibrosis in MFG-E8 -/-TSK/+ mice were also enhanced ( Figures 5D and E) . Lung fibrosing scores were significantly higher in MFG-E8 -/-TSK/+ mice than in MFG-E8 WT TSK/+ mice ( Figure 5F ). The numbers of α-SMA+ myofibroblasts, CD3+ T cells, and CD68+ macrophages in the lungs of MFG-E8 -/-TSK/+ mice were significantly higher than those in the lungs of MFG-E8 WT TSK/+ mice ( Figure 5G ). . Quantification of relative levels was accomplished via densitometry using ImageJ software (National Institutes of Health). Values are the mean ± SEM relative to mRNA and protein levels in untreated fibroblasts (set to 1). * = P < 0.05; ** = P < 0.01.
IL-6 signaling is also recognized as being involved in the development and progression of fibrosis in SSc (32, 44) . Expression of mRNA for type I collagen and IL-6 in the lungs of MFG-E8 -/-TSK/+ mice was significantly higher than that in the lungs of MFG-E8 WT TSK/+ mice ( Figure 5H ). TSK mice produce specific autoantibodies, including ANAs and anti-topo I, that can also be shown in SSc patients (43) . In our study, serum levels of ANAs and anti-topo I were significantly higher in MFG-E8 -/-TSK/+ mice than in MFG-E8 WT TSK/+ mice ( Figure 5I ).
These results suggest that MFG-E8 negatively regulates fibrosis and infiltration of inflammatory cells in the skin and lungs as well as autoantibody production in TSK mice. A and B) and lung (D and E) of MFG-E8 wild-type (WT) or MFG-E8-knockout (KO) C57BL/6 mice treated with subcutaneous injections of phosphate buffered saline (PBS) or bleomycin. Bars = 100 μm in A, B, and E; 50 μm in D. C, Quantification of dermal thickness (n = 5-8 mice per group). F, Quantification of pulmonary fibrosis (n = 6 mice per group). G, Expression of mRNA for type I collagen, CCN2, α-smooth muscle actin (α-SMA), transforming growth factor β (TGFβ), and interleukin-6 (IL-6) in the skin of bleomycin-treated MFG-E8 WT mice or MFG-E8-KO mice (n = 3 per group), determined using quantitative reverse transcriptase-polymerase chain reaction. H and I, Numbers of α-SMA+ myofibroblasts, CD3+ T cells, and CD68+ macrophages (H) and CD31+ endothelial cells and NG2+ pericytes (I) in the dermis (n = 3 mice per group). In C and F, values are the mean ± SEM. In G-I, values are the mean ± SEM relative to mRNA levels and cell counts in WT mice (set to 1). * = P < 0.05; ** = P < 0.01.
Administration of rMFG-E8 significantly inhibits bleomycin-induced dermal fibrosis in mice. Finally, we examined the effect of rMFG-E8 injection on bleomycin-induced dermal fibrosis in mice. Bleomycin-enhanced dermal thickness was significantly inhibited by the subcutaneous injection of rMFG-E8 ( Figures 6A and B) . Masson's trichrome staining revealed that bleomycin-induced dermal fibrosis was significantly suppressed by rMFG-E8 injection ( Figure 6C ). In addition, Figure 5 . Exacerbation of skin and pulmonary fibrosis in TSK mice by deficiency of milk fat globule-associated protein with epidermal growth factorand factor VIII-like domains (MFG-E8). A, B, D, and E, Representative images of hematoxylin and eosin staining (A and D) or Masson's trichrome staining (B and E) of the skin (A and B) and lung (D and E) of MFG-E8 wild-type TSK (WT/TSK) mice and MFG-E8-knockout TSK (KO/TSK) mice. Bars = 50 μm in A, B, and D; 100 μm in E. C, Quantification of hypodermal thickness in mice (n = 5 per group). F, Quantification of pulmonary fibrosis in mice (n = 10 per group). G, Numbers of α-smooth muscle actin-positive (α-SMA+) myofibroblasts, CD3+ T cells, and CD68+ macrophages in the lung (n = 3 mice per group). H, Expression of mRNA for type I collagen and interleukin-6 (IL-6) in the lung (n = 3 mice per group), determined using quantitative reverse transcriptase-polymerase chain reaction. I, Serum levels of antinuclear antibodies (ANAs) and anti-topoisomerase I (anti-topo I) in mice (n = 10-16 per group). In C and F, values are the mean ± SEM. In G and H, values are the mean ± SEM relative to cell counts and mRNA levels in WT TSK mice (set to 1). In I, symbols represent individual mice; bars show the mean ± SEM. * = P < 0.05; ** = P < 0.01. the increase in the amount of collagen in the skin induced by bleomycin treatment was also inhibited by rMFG-E8 injection ( Figure 6D ). The increase in the numbers of α-SMA+ myofibroblasts, CD68+ macrophages, and CD3+ T cells in lesional skin in bleomycin-treated mice was significantly decreased by rMFG-E8 injection ( Figure 6E ). These results suggest that rMFG-E8 acts to inhibit bleomycin-induced skin fibrosis in vivo.
DISCUSSION
We previously reported that MFG-E8 is mainly expressed in ECs and pericytes/VSMCs in human and mouse skin (15) . In human and mouse melanoma tumors, MFG-E8 is also mainly expressed by pericytes/pericyte precursors, and MFG-E8 enhances angiogenesis and tumor growth (13, 18) . In the present Figure 6 . Significant inhibition of bleomycin (Bleo)-induced dermal fibrosis in mice by administration of recombinant milk fat globule-associated protein with epidermal growth factor-and factor VIII-like domains (rMFG-E8). A and C, Representative images of hematoxylin and eosin staining (A) or Masson's trichrome staining (C) of the skin of mice treated with subcutaneous injections of phosphate buffered saline (PBS) or bleomycin, or treated with subdermal injections of rMFG-E8 or PBS. Bars = 50 μm. B, Quantification of dermal thickness in mice (n = 10 per group). D, Quantification of soluble collagen amount in skin tissue (n = 7 mice per group). E, Numbers of α-smooth muscle actin-positive (α-SMA+) myofibroblasts, CD68+ macrophages, and CD3+ T cells in the dermis (n = 4-6 mice per group). In B, values are the mean ± SEM. In D and E, values are the mean ± SEM relative to soluble collagen amount and cell counts in mice injected both subcutaneously and subdermally with PBS. * = P < 0.05; ** = P < 0.01. study, we found that MFG-E8 expression in ECs and pericytes/ VSMCs was reduced in sclerotic skin lesions of SSc patients. It has been suggested that vasculopathy and dysfunction of ECs might be associated with the development of skin fibrosis in SSc patients (1, 2) . Additionally, it has been reported that numbers of pericytes/ VSMCs in all types of blood vessels in lesional skin are decreased in SSc patients (2, 25, 45) . Collectively, vasculopathy-induced dysfunction of and reduction in ECs and pericytes/VSMCs might be associated with decreased expression of MFG-E8 in lesional skin of SSc patients. Similar to our results, expression of MFG-E8 was reduced in smooth muscle cells around fibrosing respiratory tracts of asthma patients as well as in cirrhotic livers (19, 46) , which suggests that reduced expression of MFG-E8 might be involved in the pathogenesis of fibrosis in various organs and tissues.
It is considered that the binding of latent TGFβ complex to αv integrin is necessary to release an active form of TGFβ. For example, in SSc fibroblasts, αv integrin was found to be overexpressed and to consequently increase the activation of TGFβ, resulting in enhancement of TGFβ signaling and fibrosis in vitro (25) . In addition, using fibrillin 1 mutant mice, enhancement of skin fibrosis was found to be caused by modulation of binding between αv integrin and latent TGFβ (26) . In our study, we determined that rMFG-E8 inhibited latent TGFβ-enhanced TGFβ signaling and fibrosis in SSc fibroblasts. Furthermore, we confirmed that the inhibition of latent TGFβ-enhanced TGFβ signaling by rMFG-E8 was partly mediated via the interaction of the RGD domain of MFG-E8 with αv integrin on fibroblasts.
With respect to inhibition of TGFβ signaling by MFG-E8, An et al reported that rMFG-E8 inhibited TGFβ-enhanced TGFβ signaling and fibrosis in hepatic stellate cells through inhibition of TGFβRI expression (19) . However, we could not confirm inhibition of TGFβ-enhanced TGFβ signaling by rMFG-E8 in SSc fibroblasts. In addition, expression of mRNA for TGFβRI and TGFβRII in SSc fibroblasts was not inhibited by rMFG-E8 in our study, which suggests that inhibition of latent TGFβ-enhanced TGFβ signaling in SSc fibroblasts by rMFG-E8 might not depend on inhibition of TGFβR expression.
Consistent with our findings, it has been reported that MFG-E8-KO mice develop exaggerated pulmonary fibrosis upon intratracheal bleomycin administration owing to a defect in collagen removal by macrophages (9) . Although skin fibrosis was not examined in that previous study, we found that bleomycin-induced skin fibrosis in MFG-E8-KO mice was significantly exacerbated compared with that in WT mice and that expression of mRNA for type I collagen and numbers of α-SMA+ myofibroblasts in the skin of bleomycin-treated MFG-E8-KO mice were enhanced, suggesting that overproduction of collagen from myofibroblasts may be associated with enhancement of skin fibrosis in MFG-E8-KO mice.
We demonstrated that skin and pulmonary fibrosis in TSK mice were exacerbated by deficiency of MFG-E8. Our results suggest that MFG-E8 might negatively regulate fibrosis and inflammatory cell infiltration in the skin and lungs as well as autoantibody production in TSK mice. Although a tandem duplication within the fibrillin 1 gene has been suggested to cause the TSK phenotype (41) (42) (43) , the mechanisms of pathogenesis of fibrosis in TSK mice are still unknown. Activation of TGFβ signaling possibly plays an important role in the pathogenesis of fibrosis in TSK mice (47, 48) . Our results suggest that deficiency of MFG-E8 might enhance the release of active TGFβ from latent TGFβ complex in TSK mice, leading to exacerbation of fibrosis. However, the precise mechanisms underlying the increase in fibrosis in TSK mice caused by MFG-E8 deficiency require further study.
We demonstrated that administration of rMFG-E8 significantly inhibited bleomycin-induced dermal fibrosis in mice. These in vivo results are consistent with our in vitro results, which suggest that MFG-E8 might have therapeutic potential by inhibiting TGFβ signaling under pathogenic conditions. Consistent with our results, it has been reported that rMFG-E8 administration inhibited thioacetamide-induced liver fibrosis in mice and reduced the number of α-SMA+ myofibroblasts (19) , warranting that rMFG-E8 may have therapeutic potential for fibrosis in several organs.
In conclusion, we have, for the first time, demonstrated that MFG-E8 inhibited latent TGFβ-enhanced TGFβ signaling and fibrosis mediated by the interaction of the RGD domain in MFG-E8 with αv integrin in SSc fibroblasts. Vasculopathy may be responsible for the reduced MFG-E8 expression in ECs and pericytes/ VSMCs in sclerotic skin lesions, and this reduction may be related to poor angiogenesis and prominent dermal fibrosis around blood vessels. Our in vivo findings suggest that MFG-E8 might negatively regulate skin and pulmonary fibrosis in bleomycin-treated mice and TSK mice. A deficient antifibrotic effect of MFG-E8 may be involved in the pathogenesis of SSc, and integrin-modulating therapy, such as administration of rMFG-E8, could be promising for the treatment of fibrosis in SSc.
